Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed ...

Indoco Remedies receives US FDA final approval for its ANDA for lacosamide oral solution USP, 10 mg/mL: Our Bureau, Mumbai Friday, January 30, 2026, 14:30 Hrs [IST] Indoco Remedie ...

EXCLUSIVE — The Environmental Protection Agency has begun a multiyear study to determine the maximum safe level of fluoride in the nation’s drinking water, advancing a key objective of the “Make ...

Lacosamide Oral Solution is used in the treatment of partial onset seizures and primary generalised tonic-clonic seizures in adults and children aged four years and above with epilepsy.

Indoco Remedies receives USFDA approval to market generic Lacosamide oral solution for epilepsy treatment. Manufactured in Goa facility.

Kymera Therapeutics KYMR announced that it has begun dosing patients in the phase IIb BREADTH study of KT-621 for moderate-to ...

Investigator sought to determine whether nelfinavir mesylate plus chemoradiation and image-guided brachytherapy could improve disease-free survival for patients with stage III cervical cancer.

Altria Group (NYSE:MO) executives highlighted “continued momentum” in 2025, pointing to adjusted earnings growth, cash ...

A new drug application (NDA) has been submitted to the FDA seeking approval of lirafugratinib (RLY-4008), a selective FGFR2 ...

Optimized treatment of lichen planopilaris should be individualized in the context of presenting symptoms and features, according to a newly tweaked algorithm.

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.